Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Logicbio Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is concentrated under 1 distinct examiner and 1 distinct art unit, indicating that the company's current prosecution efforts are highly localized. For a practitioner, this means there is no administrative complexity from multiple examiners or different art unit standards. The prosecution strategy can be entirely focused on the specific practices of the 1 distinct art unit.
The busiest examiner for this portfolio is GRABER, JAMES J, who is responsible for 1 busiest examiner pending action. Since the total pending office actions count is 1, GRABER, JAMES J is the sole examiner currently handling the company's active prosecution. This allows the practitioner to focus all their efforts on a single interaction at the USPTO. The outcome of the pending matter will be determined by the specific examination approach of GRABER, JAMES J within the 1 distinct art unit. This concentration allows for a more direct and efficient prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 1 | 47.0% | +58.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603935 | MONITORING GENE THERAPY | GRABER, JAMES J | 19d |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17603935 | MONITORING GENE THERAPY | GRABER, JAMES J | 1631 | §103 | Non-Final OA | 19d | Pending | Oct 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLogicbio Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
James J Graber has the most, with 1 of Logicbio Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.